

**DEPARTMENT OF PULMONARY MEDICINE
POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH, CHANDIGARH**

Applications are invited for one post of Study Coordinator under the drug trial entitled "RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP PHASE 3 STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF SAR440340/REGN3500/ ITEPEKIMAB (ANTI-IL-33 MAB) IN PATIENTS WITH MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)." funded by Sanofi Healthcare India Pvt. Limited. The post is purely on contract basis initially for up to one year, or until completion of Drug Trial.


Study Coordinator (one Post)

Eligibility: MSc (Life Sciences)/BDS/MDS/MPH
Desirable: one-year clinical experience preferably
Age limit: Below 30 years.
Emoluments: Rs.33000/-

Interested candidates may submit their two-page bio-data, along with self-attested testimonials and any other supporting document, to the office of the undersigned by 4:00 PM on 19th Jan 2024, clearly mentioning the post applied for. This bio-data must provide clear and complete information on the candidate's eligibility and relevant experience for post applied for, and include his/her e-mail address and mobile number.

Interview will be held at 10:30 a.m. on 20th Jan 2024 at the Committee Room of Internal Medicine, Nehru Hospital, 4th Floor, F' Block, PGIMER, Chandigarh. No TA/DA will be admissible for attending the interview.

No. Pulm/2024/0022
Dated 18/01/2024


Dr. Sahajal Dhorria
Principal Investigator & Associate Professor
Dept. of Pulmonary Medicine,
PGIMER, Chandigarh

**Dr. Sahajal Dhorria
Associate Professor
Deptt. of Pulmonary Medicine
PGIMER, Chandigarh**